Cargando…
A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study
PURPOSE: Leucovorin is commonly used as folate supplement in 5-fluorouracil-based chemotherapy, but needs to be converted to active 5,10-methylenetetrahydrofolate (methyleneTHF) intracellularly. This provides for interindividual differences. MethyleneTHF has recently been developed into the stable,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281361/ https://www.ncbi.nlm.nih.gov/pubmed/25342290 http://dx.doi.org/10.1007/s00280-014-2611-9 |
_version_ | 1782350982328352768 |
---|---|
author | Wettergren, Yvonne Taflin, Helena Odin, Elisabeth Kodeda, Karl Derwinger, Kristoffer |
author_facet | Wettergren, Yvonne Taflin, Helena Odin, Elisabeth Kodeda, Karl Derwinger, Kristoffer |
author_sort | Wettergren, Yvonne |
collection | PubMed |
description | PURPOSE: Leucovorin is commonly used as folate supplement in 5-fluorouracil-based chemotherapy, but needs to be converted to active 5,10-methylenetetrahydrofolate (methyleneTHF) intracellularly. This provides for interindividual differences. MethyleneTHF has recently been developed into the stable, distributable drug, Modufolin(®). The aim was to compare the concentration of folate metabolites in tumor, mucosa, and plasma of patients with colon cancer after administration of Modufolin(®) or Isovorin(®) (levo-leucovorin). METHODS: Thirty-two patients scheduled for colon resection were randomized to receive Modufolin(®) or Isovorin(®) at dosage of 60 or 200 mg/m(2). The study drug was given as one i.v. bolus injection after anesthesia. Plasma was collected for pharmacokinetic (PK) analysis before, during, and after surgery. Tissue biopsies were collected at surgery. Folate metabolites were analyzed by LC-MS/MS. RESULTS: MethyleneTHF and THF concentrations were significantly higher in mucosa (p < 0.01, both dosages) and tumors (p < 0.01, 200 mg/m(2)) after Modufolin(®) as compared to Isovorin(®) administration. The results correlated with PK observations. The Modufolin(®) to Isovorin(®) C (max) ratio for methyleneTHF was 113 at 200 mg/m(2) and 52 at 60 mg/m(2); the AUC(last) ratios were 17 and 9, respectively. The THF plasma concentrations were also higher after Modufolin(®) administration (C (max) ratio 23, AUC(last) ratio 13 at 200 mg/m(2); C (max) ratio 15, AUC(last) ratio 11 at 60 mg/m(2)). CONCLUSION: Modufolin(®) administration resulted in significantly higher methyleneTHF levels than Isovorin(®) and may potentially increase the efficacy of 5-fluorouracil-based chemotherapy. The results encourage further evaluation of Modufolin(®) as a substitute to Isovorin(®) including the potential clinical benefits. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00280-014-2611-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4281361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-42813612015-01-05 A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study Wettergren, Yvonne Taflin, Helena Odin, Elisabeth Kodeda, Karl Derwinger, Kristoffer Cancer Chemother Pharmacol Original Article PURPOSE: Leucovorin is commonly used as folate supplement in 5-fluorouracil-based chemotherapy, but needs to be converted to active 5,10-methylenetetrahydrofolate (methyleneTHF) intracellularly. This provides for interindividual differences. MethyleneTHF has recently been developed into the stable, distributable drug, Modufolin(®). The aim was to compare the concentration of folate metabolites in tumor, mucosa, and plasma of patients with colon cancer after administration of Modufolin(®) or Isovorin(®) (levo-leucovorin). METHODS: Thirty-two patients scheduled for colon resection were randomized to receive Modufolin(®) or Isovorin(®) at dosage of 60 or 200 mg/m(2). The study drug was given as one i.v. bolus injection after anesthesia. Plasma was collected for pharmacokinetic (PK) analysis before, during, and after surgery. Tissue biopsies were collected at surgery. Folate metabolites were analyzed by LC-MS/MS. RESULTS: MethyleneTHF and THF concentrations were significantly higher in mucosa (p < 0.01, both dosages) and tumors (p < 0.01, 200 mg/m(2)) after Modufolin(®) as compared to Isovorin(®) administration. The results correlated with PK observations. The Modufolin(®) to Isovorin(®) C (max) ratio for methyleneTHF was 113 at 200 mg/m(2) and 52 at 60 mg/m(2); the AUC(last) ratios were 17 and 9, respectively. The THF plasma concentrations were also higher after Modufolin(®) administration (C (max) ratio 23, AUC(last) ratio 13 at 200 mg/m(2); C (max) ratio 15, AUC(last) ratio 11 at 60 mg/m(2)). CONCLUSION: Modufolin(®) administration resulted in significantly higher methyleneTHF levels than Isovorin(®) and may potentially increase the efficacy of 5-fluorouracil-based chemotherapy. The results encourage further evaluation of Modufolin(®) as a substitute to Isovorin(®) including the potential clinical benefits. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00280-014-2611-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-10-24 2015 /pmc/articles/PMC4281361/ /pubmed/25342290 http://dx.doi.org/10.1007/s00280-014-2611-9 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Wettergren, Yvonne Taflin, Helena Odin, Elisabeth Kodeda, Karl Derwinger, Kristoffer A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study |
title | A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study |
title_full | A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study |
title_fullStr | A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study |
title_full_unstemmed | A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study |
title_short | A pharmacokinetic and pharmacodynamic investigation of Modufolin(®) compared to Isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study |
title_sort | pharmacokinetic and pharmacodynamic investigation of modufolin(®) compared to isovorin(®) after single dose intravenous administration to patients with colon cancer: a randomized study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281361/ https://www.ncbi.nlm.nih.gov/pubmed/25342290 http://dx.doi.org/10.1007/s00280-014-2611-9 |
work_keys_str_mv | AT wettergrenyvonne apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT taflinhelena apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT odinelisabeth apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT kodedakarl apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT derwingerkristoffer apharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT wettergrenyvonne pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT taflinhelena pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT odinelisabeth pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT kodedakarl pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy AT derwingerkristoffer pharmacokineticandpharmacodynamicinvestigationofmodufolincomparedtoisovorinaftersingledoseintravenousadministrationtopatientswithcoloncancerarandomizedstudy |